Syndrome News and Research

RSS

Scientists seek broad, versatile countermeasures effective against several kinds of viruses, other pathogens

A group of University of Washington scientists is seeking broad, versatile countermeasures effective against several different kinds of viruses and other pathogens. The investigators are part of a national push for faster responses to unexpected infectious agents.

9 Apr 2014

Alkermes announces results from phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia

Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.

8 Apr 2014

Research suggests that person can slow aging process by exercising regularly

New research by Canadian sports medicine physician Mark Tarnopolsky, MD, PhD, suggests that a person can slow the speed at which they age by exercising regularly. Dr. Tarnopolsky presented his research titled, "Exercise as a Countermeasure for Aging: From Mice to Humans" today at the 23rd Annual Meeting of the American Medical Society for Sports Medicine (AMSSM). Dr. Tarnopolsky discussed how regular exercise not only improves the quality of life but can also extend a person's lifespan by up to five years.

8 Apr 2014

Study examines links between parental obesity and risk of autism developmental in child

Several studies have looked at possible links between maternal obesity during pregnancy and the risk of developmental disorders in the child. However, paternal obesity could be a greater risk factor than maternal obesity, according to a new study from the Norwegian Institute of Public Health.

8 Apr 2014

Ambit initiates Phase 2 study of quizartinib in acute myeloid leukemia patients

Ambit Biosciences, a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the Phase 2 cohort of the MD Anderson Cancer Center-sponsored Phase 1/2 study of quizartinib in combination with either 5-azacitidine or low dose cytarabine for previously untreated FLT3-ITD positive acute myeloid leukemia (AML) patients age 60 or older, or FLT3-ITD positive AML patients 18 years of age or older in first relapse.

7 Apr 2014

Researchers discover hotspot L205R mutation is closely associated with adrenocortical tumors

Chinese researchers from Rui-Jin Hospital, Shanghai Jiao-Tong University School of Medicine, BGI, and other institutions have discovered that the activating hotspot L205R mutation in PRKACA gene was closely associated with adrenocortical tumors (ACTs), and the relationship of recurrently mutated DOT1L and CLASP2 with ACTs' other subtypes.

7 Apr 2014

Blood sample could diagnose many types of solid cancers

A blood sample could one day be enough to diagnose many types of solid cancers, or to monitor the amount of cancer in a patient's body and responses to treatment. Previous versions of the approach, which relies on monitoring levels of tumor DNA circulating in the blood, have required cumbersome and time-consuming steps to customize it to each patient or have not been sufficiently sensitive.

7 Apr 2014

Transgenomic to provide genetic testing services for Raptor’s clinical trial

Transgenomic, Inc., a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced an agreement with Raptor Pharmaceuticals Inc. to provide genetic testing services for Raptor's clinical trial (RP103-MITO-001) evaluating RP103 as a potential treatment for Leigh syndrome and other inherited mitochondrial disorders.

4 Apr 2014

Neuroinflammation levels higher in patients with chronic fatigue syndrome

Researchers at the RIKEN Center for Life Science Technologies, in collaboration with Osaka City University and Kansai University of Welfare Sciences, have used functional PET imaging to show that levels of neuroinflammation, or inflammation of the nervous system, are higher in patients with chronic fatigue syndrome than in healthy people.

4 Apr 2014

Longer looks: New doubts about shaken baby syndrome; arresting the mentally ill; self-help therapy

A number of reexamined cases in recent years - aided by new technology and debate among medical experts - have put proponents of the (Shaken Baby Syndrome) hypothesis on the defensive.

4 Apr 2014

FDA clears Omeros' OMS721 IND for inhibition of complement‑mediated TMAs

Omeros Corporation today announced that its Investigational New Drug Application (IND) to evaluate OMS721 for the inhibition of complement‑mediated thrombotic microangiopathies (TMAs) has been cleared by the U.S. Food and Drug Administration.

3 Apr 2014

Patients who stay longer in ICU have substantial physical impairments 2 years later

Patients have substantial physical impairments even two years after being discharged from the hospital after a stay in an intensive care unit (ICU), new Johns Hopkins research suggests.

3 Apr 2014

Ablative Solutions’ Peregrine System Infusion Catheter receives FDA clearance

Ablative Solutions, Inc., a privately-held clinical stage company, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Peregrine System(TM) Infusion Catheter.

3 Apr 2014

Researchers investigate how gene regulation affects evolution and development

Johannes Gutenberg University Mainz (JGU) has received EUR 900,000 for three years to investigate, jointly with the Institute of Molecular Biology (IMB), how gene regulation affects evolution and development.

3 Apr 2014

New evidence indicates another risk factor for young adults consuming energy drinks

Newfound evidence indicates another risk factor for young adults consuming energy drinks. A research team representing six American universities found that the frequency of energy drink use is associated with increased odds of illicit prescription stimulant medication use.

3 Apr 2014

Drinking two or more cups of coffee each day reduces risk of death from liver cirrhosis by 66%

New research reveals that consuming two or more cups of coffee each day reduces the risk of death from liver cirrhosis by 66%, specifically cirrhosis caused by non-viral hepatitis. Findings in Hepatology, a journal published by Wiley on behalf of the American Association for the Study of Liver Diseases, show that tea, fruit juice, and soft drink consumption are not linked to cirrhosis mortality risk. As with previous studies heavy alcohol use was found to increase risk of death from cirrhosis.

2 Apr 2014

Syndrome News and Research

Scientists seek broad, versatile countermeasures effective against several kinds of viruses, other pathogens

Alkermes announces results from phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia

Research suggests that person can slow aging process by exercising regularly

Study examines links between parental obesity and risk of autism developmental in child

Ambit initiates Phase 2 study of quizartinib in acute myeloid leukemia patients

Researchers discover hotspot L205R mutation is closely associated with adrenocortical tumors

Blood sample could diagnose many types of solid cancers

Transgenomic to provide genetic testing services for Raptor’s clinical trial

Neuroinflammation levels higher in patients with chronic fatigue syndrome

Longer looks: New doubts about shaken baby syndrome; arresting the mentally ill; self-help therapy

FDA clears Omeros' OMS721 IND for inhibition of complement‑mediated TMAs

Patients who stay longer in ICU have substantial physical impairments 2 years later

Ablative Solutions’ Peregrine System Infusion Catheter receives FDA clearance

Researchers investigate how gene regulation affects evolution and development

New evidence indicates another risk factor for young adults consuming energy drinks

Drinking two or more cups of coffee each day reduces risk of death from liver cirrhosis by 66%

Ablative Solutions' Peregrine System Infusion Catheter receives FDA clearance

Study shows important parallels between epidemic of HIV/AIDS and opioid addiction

Study of diet and aging in monkeys shows significant reduction in mortality

Discovery could lead to new therapies for people with celiac disease

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News